Ceo
CurrentNormOxys is a drug development company which was founded in 2004 by Professor Claude Nicolau, Professor Jean-Marie Lehn, Conrad Bletzer, esq. and colleagues. It is headquartered in Boston, Massachusetts with laboratories in Boston.NormOxys has discovered and is currently developing a novel class of small molecule drug, OXY111A, which inhibit PI3K . Potential clinical indications include cancer, cardiovascular disease and several others.